Sanofi oral selective estrogen receptor (ER) degrader (SERD)
< 1 minute read
Sep. 18, 2021
SAR439859: An Oral Selective Estrogen Receptor Degrader
SAR439859
oral sel. estrogen receptor degrader (SERD) 400 mg QD, in Ph. II for ER+/HER2- BC from MTS of ER binders, opt. for degrd./antag. Mol. Cancer Ther., Dec. 11, 2020 Sanofi, Vitry-sur-Seine, FR / Cambridge MA
Loading...
